SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy
Condition: Myelodysplastic Syndromes Intervention: Drug: SX-682 Sponsors: Syntrix Biosystems, Inc.; H. Lee Moffitt Cancer Center and Research Institute; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials